AstraZeneca, National Institute of Pulmonology sign strategic coop deal
From left: Dr Mátyás Faluvégi, Dr. Krisztina Bogos, Kuuno Vaher.
The Korányi National Institute of Pulmonology and AstraZeneca's domestic subsidiary have signed a strategic cooperation agreement. The aims of the collaboration include the expansion of joint research and development activities in the field of obstructive and cancer-related lung diseases, the analysis and evaluation of available data and the appropriate education of pulmonary specialists and patients, according to a press release sent to the Budapest Business Journal.
The agreement was signed by Dr. Krisztina Bogos, general director of the Korányi National Institute of Pulmonology; Kuuno Vaher, director of AstraZeneca's Central European Cluster; and Dr. Mátyás Faluvégi, director of AstraZeneca's Hungarian Research Division on April 29, on the occasion of the upcoming World Asthma Day.
Under the professional partnership, the parties will work closely together in basic and translational clinical research related to obstructive pulmonary diseases (COPD, asthma) and lung cancer. An important pillar of the collaboration is the broadening of the analysis and evaluation of available data sets for effective patient care. The agreement will also include programs to help diagnose patients faster and more efficiently.
The joint project between the innovative pharmaceutical company and the institute will also focus on the appropriate education of pulmonary specialists and patients. The collaboration will also provide the opportunity to build closer links with primary care and the existing network of pulmonary care providers.
"The Korányi National Institute of Pulmonology is a center of national importance and competence, representing the highest level of progressiveness in pulmonary care. It has always been important for us to provide patients with the highest possible level of care, adequate quality of information, and the use of state-of-the-art diagnostic and therapeutic options. Our clinical work is traditionally accompanied by our research efforts, which we strive to carry out partly in collaboration with the institute's research units and partly with national and international external partners," said Dr. Bogos.
"Thanks to the professional partnership that has now been established, it is expected that we will be able to find the patients concerned more efficiently, make an early and accurate diagnosis, provide patient care and treatment, and reduce mortality rates," she added.
Vaher noted, "AstraZeneca is one of the leading pharmaceutical companies in Hungary in terms of the number of clinical trials launched in the last two years, with an annual R&D expenditure of around HUF 2 billion. We have been working for decades to make modern therapies with long-lasting results available in Hungary, but we also run a number of educational programs. Our main therapeutic areas include oncology, cardiovascular, renal, metabolic, and immunology."
"One of our key priority areas of research is the development of molecules for respiratory diseases, so it was natural for us to further deepen our collaboration with the National Comprehensive Center for Respiratory Diseases," he added.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.